Sponsor & Developer Portfolio
Emory University
Clinical development pipeline, platform architecture, and registered trial tracking for Emory University vaccine candidates.
3
Candidates
3
Target Diseases
4
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 3
Platform Technologies
Biological (unspecified platform): 3
Target Pathogens & Indications
HPV Meningococcal disease RSV
Vaccine Pipeline Candidates (3)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Phase 3 Clinical Trial
ctgov-gardasil-9-emory-university
Gardasil-9
Target: HPV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2028-09 (registry estimate)
Phase 3 Clinical Trial
ctgov-moderna-rsv-vaccine-emory-university
Moderna RSV vaccine
Target: RSV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-07 (registry estimate)
Phase 3 Clinical Trial
ctgov-trumenba-emory-university
Trumenba
Target: Meningococcal disease
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-12 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.